Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety of Asciminib in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Interim Results from the Phase 2 ASC2ESCALATE Trial in the Cohort of Patients (Pts) after 1 Prior Tyrosine Kinase Inhibitor (TKI)

Ehab L. Atallah, Moshe Y. Levy, Paul B. Koller, Koji Sasaki, Srinivas K Tantravahi, David Andorsky, Celesteann T Bremer, Joshua F Zeidner, Marlise R. Luskin, Reinhold Munker, Daisy Yang, Dramane Laine, John Sabo, Ennan Gu, Michael J. Mauro, Jorge E. Cortes

Blood (2024) 144 (Supplement 1): 479.

https://doi.org/10.1182/blood-2024-200717

Published: 2024

Journal Articles

ASC2ESCALATE: A US Phase 2, Open-Label, Single-Arm, Dose-Escalation Study of Asciminib (ASC) Monotherapy in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) As Second-Line (2L) and First-Line (1L) Treatment

Ehab L. Atallah, Michael Mauro, Koji Sasaki, Moshe Levy, Paul B. Koller, Daisy Yang, Dramane Laine, John Sabo, Ennan GU, Jorge Cortes

Blood (2023) 142 (Supplement 1): 6389.

https://doi.org/10.1182/blood-2023-186974

Published: 2023

Journal Articles

Stimulus MDS-US Trial in Progress: Evaluating Sabatolimab in Combination with Hypomethylating Agents (HMAs) in Patients with Intermediate-, High-, or Very High-Risk Myelodysplastic Syndrome (MDS)

Amer M. Zeidan, Amy E. DeZern, Uma Borate, Krissy Kobata, Susan E. Ide, John Sabo, Pedro Marques Ramos, Haiying Sun, Roger M. Lyons, Guillermo Garcia-Manero

Blood (2022) 140 (Supplement 1): 4069–4070.

https://doi.org/10.1182/blood-2022-167259

Published: 2022

Journal Articles

Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program

Blood (2021) 138 (Supplement 1): 4669.

https://doi.org/10.1182/blood-2021-145626

Published: 2021